Masayuki Senda
8PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Aug 26, 2020
Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study).Munehide Matsuhisa, Masato Odawara, Takahisa Hirose
|Jul 23, 2020
Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study).Masato Odawara, Munehide Matsuhisa, Takahisa Hirose
|Jun 30, 2020
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).Kazunori Utsunomiya, Ryusuke Koshida, Seigo Kakiuchi
|Feb 09, 2020
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda
|Aug 08, 2019
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study).Kohei Kaku, Yusuke Naito, Masayuki Senda
|Jun 15, 2019
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi
Pageof 2
